CPX-351 Plus Quizartinib

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

What's the purpose of the trial?

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Quizartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The goal of this study is to learn if the combination of CPX-351 and quizartinib can help to control acute myeloid leukemia and myelodysplastic syndrome.
Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
52
Last Updated
2 months ago
Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • CPX-351 is a drug that combines cytarabine and daunorubicin, and is approved for the treatment of acute myeloma leukemia. It is currently being studied for use in several other cancers.
  • Quizartinib is a tyrosine kinase inhibitor that is being studied for use in acute myeloid leukemia (AML).

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Frontline Cohort: CPX-351 + Quizartinib

Accepting patients

Relapsed or Refractory Cohort: CPX-351 + Quizartinib

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.